stockrowCoherus Oncology, Inc.
CHRSCoherus Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $42.2 million, up 59.8% from fiscal 2024.
- Revenue
- +23.4%
- EPS
- +18.1%
- Free cash flow
- +26.6%
- Total debt
- +42.2%
Quarter to September 2026, against a year earlier
Follow CHRS
Alert me
Coherus Oncology, Inc. (CHRS) Return on invested capital
Coherus Oncology, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −2,805.2% (fiscal 2017) to 67.9% (fiscal 2020); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 1,795.44 |
| FY2024 | −1,795.4% | (1,717.14) |
| FY2023 | −78.3% | 34.80 |
| FY2022 | −113.1% | 72.59 |
| FY2021 | −185.7% | (253.61) |
| FY2020 | 67.9% | 4.34 |
| FY2019 | 63.6% | 63.58 |
| FY2018 | 0.00% | 2,805.20 |
| FY2017 | −2,805.2% | (2,805.20) |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NBP NovaBridge Biosciences compare | 0.00% |
| UNCY Unicycive Therapeutics, Inc. compare | 0.00% |
| AVXL Anavex Life Sciences Corp. compare | 0.00% |
| CHRS Coherus Oncology, Inc. | 0.00% |
| VANI Vivani Medical, Inc. compare | 0.00% |
| NRXP NRx Pharmaceuticals, Inc. compare | 0.00% |
| HURA TuHURA Biosciences, Inc. compare | −74.2% |
| NKTX Nkarta, Inc. compare | −148.7% |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)